1418128-76-3

Upstream product

• 1462328-88-6 6-tert-butyl-2-(3-chloro-2-hydroxymethylphenyl)-3,4-dihydro-2H-isoquinolin-1-one 
• 64622-16-8 2-bromo-6-chlorobenzaldehyde 
• 1178884-68-8 6-(tert-butyl)-3,4-dihydroisoquinolin-1(2H)-one 
• 1612853-69-6 2-(6-tert-butyl-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)-6-chlorobenzaldehyde 
• 1612853-72-1 acetic acid 2-(6-tert-butyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-6-chlorobenzyl ester 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1612853-73-2 2-(6-tert-butyl-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)-6-(5-(5-((2-methoxyethylamino)methyl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzyl acetate 
• 1612853-22-1 6-tert-butyl-2-[2-hydroxymethyl-3-(5-{5-[(2-methoxyethylamino)methyl]pyridin-2-ylamino}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-3,4-dihydro-2H-isoquinolin-1-one 

Relevant academic research and scientific papers

INHIBITORS OF BRUTON'S TYROSINE KINASE

This application discloses the Btk inhibitor compounds 6-tert-Butyl-8-fluoro-2-{3- hydroxymethyl-4-[1-methyl-5-(1'-methyl-1',2',3',4',5',6'-hexahydro-[3,4']bipyridinyl-6-ylamino)- 6-oxo-1,6-dihydro-pyridazin-3-yl]-pyridin-2-yl}-2H-phthalazin-1-one, 2-(2-{3-[5-(5-Azetidin-1- ylmethyl-1-methyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl]-2- hydroxymethyl-phenyl}-8-fluoro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methyl-propionitrile, and 6-tert-Butyl-2-[2-hydroxymethyl-3-(5-{5-[(2-methoxy-ethylamino)-methyl]-pyridin-2- ylamino}-6-oxo-1,6-dihydro-pyridin-3-yl)-phenyl]-3,4-dihydro-2H-isoquinolin-1-one, formulations thereof, and methods of treatment of asthma, as described herein.

NOVEL PYRROLO PYRIMIDINE DERIVATIVES

The present invention describes new pyrrolo pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel pyrrolo pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.